Pseudomonas Aeruginosa Infection Treatment Market Size will Observe Lucrative Surge by the End 2031

Pseudomonas Aeruginosa Infection Treatment Market Outlook 2031

The global pseudomonas aeruginosa infection treatment market was valued at US$ 1.3 Bn in 2021
It is estimated to rise at a CAGR of 6.6 % from 2022 to 2031
The global pseudomonas aeruginosa infection treatment market is expected to reach US$ 2.5 Bn by the end of 2031

Get Sample Copy of the Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=17156

Pseudomonas Aeruginosa Infection Treatment Market Introduction

Pseudomonas aeruginosa is a type of bacteria that can cause infections in individuals after they undergo a surgery. Infection can occur in the blood, lungs, or other parts of the body. Pseudomonas aeruginosa infection treatment includes various medications, therapies, and procedures that can reduce the infection caused to an individual. Pseudomonas aeruginosa infection is generally treated through antibiotics and other drugs.

The global pseudomonas aeruginosa infection treatment market size is estimated to increase significantly during the forecast period owing to an increase in prevalence of pseudomonas aeruginosa, surge in awareness about the disease, adoption of expansion strategies, and robust pipeline of new therapeutic in clinical trials

Increase in Incidence of Nosocomial Infections to Boost Market

Rise in prevalence of nosocomial infections associated with P. aeruginosa, such as pneumonia, urinary tract infections (UTI), cystic fibrosis, and blood stream infections, is likely to augment the global pseudomonas aeruginosa infection treatment market during the forecast period.

Increase in incidence of bacterial infections, i.e., Pseudomonas aeruginosa infections, in intensive care with no effective treatment is projected to drive the demand for newer antibacterial drugs and antibiotics for pseudomonas aeruginosa infection treatment.

According to Centers for Disease Control and Prevention (CDC) estimates, around 51,000 health care-associated P. aeruginosa infections occur in the U.S. each year. More than 6,000 (13%) of these are multidrug-resistant, with roughly 400 deaths per year attributed to these infections.

Get Report Methodology @ https://www.transparencymarketresearch.com/sample/sample.php?flag=RRM&rep_id=17156

Rapid Rise in Antibacterial Drug Resistance to Augment Market

Antibacterial drug resistance is growing rapidly across the world, as it is in the nature of bacteria to develop resistance. This has generated the urgent need of new research and innovation in the antibacterial field.

According to U.S. Centers for Disease Control and Prevention (CDC) estimates, antibacterial resistance is responsible for over 2 million infections and 23,000 deaths in the U.S. each year and an estimated 25,000 deaths due to antibacterial-resistant infections in Europe. Hence, demand for newer broad spectrum antibacterial drugs is rising. There is always a need of antibacterial drugs for the treatment of children with fatal sepsis and severe pneumonia.

High Demand for Combination Therapy for Pseudomonas Aeruginosa Infection Treatment

In terms of medication type, the global pseudomonas aeruginosa infection treatment market has been bifurcated into monotherapy and combination therapy. The combination therapy segment held around 74% of the global pseudomonas aeruginosa infection treatment market share in 2021. The segment is likely to maintain the status quo during the forecast period. The segment growth is due to increased drug resistance in monotherapy, which has resulted in a rise in the demand for combination therapy for the treatment of P. aeruginosa infection.

Combination therapy helps increase compliance, synergy, and efficacy, and reduce side-effects and cost. These factors are projected to boost the combination therapy segment. Additionally, rise in demand for combination therapy for treatment of pseudomonas aeruginosa infection is attributed to rapid onset of action, high bioavailability rate, cost saving, and high efficiency.

Enquiry before Buying @ https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=17156

Focus of Major Pharmaceutical Companies on Development of New Class of Cephalosporin Drugs

In terms of drug type, the global pseudomonas aeruginosa infection treatment market has been classified into aminoglycoside, cephalosporin, carbapenem, monobactam, and others.

The cephalosporin segment held a major share of around 40% in 2021. It is estimated to maintain the status quo during the forecast period. Expansion of the segment can be attributed to the focus of major pharmaceutical companies on the development of new class of cephalosporin for the treatment of various P. aeruginosa infections. This is expected to fuel the growth of the cephalosporin segment.

New cephalosporin (fifth-generation) was developed for the treatment of gram negative bacteria such as P. aeruginosa, methicillin-resistant staphylococcus aureus, and others. Launch of new cephalosporin class of drugs is likely to boost the segment.

Intravenous is Preferred Route of Administration for Pseudomonas Aeruginosa Infection Treatment

In terms of route of administration, the global pseudomonas aeruginosa infection treatment market has been split into nasal, oral, and intravenous.

The intravenous segment held a major share of around 40% in 2021. The segment is projected to grow and maintain its position during the forecast period due to the availability of the drugs for intravenous route, high accuracy in dosing, and rapid onset of action as compared to other routes.

Most physicians prefer intravenous route for administration of drugs because the entire administered dose reaches the systemic circulation, immediately, resulting in rapid onset of action against bacteria. This factor is expected to augment the segment.

Read Report Overview @ https://www.transparencymarketresearch.com/pseudomonas-aeruginosa-infections-treatment-market.html

Well-developed Infrastructure and Growth in Adoption of New Products Augmenting Hospital Pharmacies Segment

In terms of distribution channel, the global pseudomonas aeruginosa infection treatment market has been segregated into hospital pharmacies, retail pharmacies, and online pharmacies.

The hospital pharmacies segment held a major share of around 46% of the global market in 2021. The segment is projected to grow during the forecast period due to an increase in the number of multi-specialty hospitals in developing countries. Additionally, well-developed infrastructure and increase in adoption of new products by hospital pharmacies are likely to propel the segment during the forecast period.

Analysis of Key Players in Global Pseudomonas Aeruginosa Infection Treatment Market

The pseudomonas aeruginosa infection treatment market report concludes with the company profiles section, which includes key information about major players in the global pseudomonas aeruginosa infection treatment market. The pseudomonas aeruginosa infection treatment market companies include ALLERGAN, Teva Pharmaceutical Industries Ltd., Pfizer Inc., Lupin Pharmaceuticals, Inc., AstraZeneca, Merck & Co., Inc., Bristol-Myers Squibb Co. and Janssen Pharmaceuticals, Inc.

Get Custom Research Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=17156

Key Developments in Global Pseudomonas Aeruginosa Infection Treatment Market

In May 2021, Teva Pharmaceutical Industries Ltd. introduced erythromycin tablets with a strength of 250 mg and 500 mg. Erythromycin tablets are prescribed to treat various bacterial infections as well as rheumatic fever in patients who have an allergy to penicillin.

In February 2019, Merck announced that the FDA accepted for Priority Review a supplemental NDA for Zerbaxa to treat adult patients with nosocomial pneumonia, including ventilator-associated pneumonia, caused by certain susceptible Gram-negative microorganisms.
Each of these players has been profiled in the pseudomonas aeruginosa infection treatment market report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.

About Us

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. The firm scrutinizes factors shaping the dynamics of demand in various markets. The insights and perspectives on the markets evaluate opportunities in various segments. The opportunities in the segments based on source, application, demographics, sales channel, and end-use are analysed, which will determine growth in the markets over the next decade.

Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision-makers, made possible by experienced teams of Analysts, Researchers, and Consultants. The proprietary data sources and various tools & techniques we use always reflect the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in all of its business reports.

For More Research Insights on Leading Industries, Visit Our YouTube Channel and hit subscribe for Future Update - https://www.youtube.com/channel/UC8e-z-g23-TdDMuODiL8BKQ

Contact

Rohit Bhisey
Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com
Blog: https://tmrblog.com
Email: sales@transparencymarketresearch.com

This release was published on openPR.